BioVex Inc Logo Developing advanced biologics targeting cancer

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility.

The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

Our lead cancer technology platform, OncoVEXGM-CSF is a first-in-class oncolytic, or cancer destroying virus, that works by replicating and spreading within solid tumors (leaving healthy cells unaffected), thereby causing cancer cell death and stimulating the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free.

In May 2009 the Company commenced a Phase III study in melanoma with OncoVEXGM-CSF, following unprecedented Phase II results and following agreement with the FDA on the design of the pivotal study. In September 2009 the Company agreed a further SPA agreement with the FDA for a Phase III study in Head and Neck cancer.

Our second program is a vaccine for genital herpes, ImmunoVEXHSV2, which provides complete protection in animal models of the disease. The vaccine has been authorized to commence clinical testing in the UK.

ASCO 2009 poster presentations

Biovex Poster Presentation - Melanoma

ASCO 2009 melanoma poster

Biovex Poster Presentation - A phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy in untreated stage III/IV squamous cell cancer of the head and neck

ASCO 2009 head and neck cancer poster

News

January 4, 2010
BioVex appoints Tim Hanke as VP Commercial Operations

BioVex has appointed Tim Hanke as VP Commercial Operations. Mr Hanke will be responsible for preparing for the commercialization of BioVex’s investigational product, OncoVEXGM-CSF.
+ read more

 

November 10, 2009
BioVex completes $70 million financing to conclude pivotal study with its pioneering cancer treatment, OncoVEXGM-CSF

The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEXGM-CSF for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
+ read more

 

November 2, 2009
Biovex announces publication of
Phase 2 Melanoma Results with OncoVEXGM-CSF in the
Journal of Clinical Oncology

Complete durable eradication of disease achieved in a significant number of patients with investigational therapy for advanced Stage III and Stage IV melanoma
+ read more

 

September 15, 2009
BioVex agrees SPA with the FDA for a pivotal Phase III study with
OncoVEXGM-CSF in head and neck cancer

+ read more

 

May 15, 2009
BioVex to announce updated survival data from a Phase II clinical study of OncoVEXGM-CSF in metastatic melanoma at the 2009 American Society of Clinical Oncology meeting

+ read more + view poster

 
Copyright © BioVex 2006-10 legal notice | site map